Chemotherapy News and Research

Latest Chemotherapy News and Research

Halaven (eribulin mesylate) approved for treatment of liposarcoma

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug.

28 Jan 2016

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

Building upon more than two decades of basic research conducted at Children's Hospital Los Angeles, Araz Marachelian, MD, of CHLA, and her colleagues at pediatric academic centers across the U. S., have shown that an immunotherapy that until now has only been available to patients enrolled in research studies, is equivalent to the product that has been manufactured for commercial use and can be made available to all patients.

28 Jan 2016

Nutrition and breast cancer; starving triple negative breast cancer cells to death: an interview with Associate Professor Jeff Holst

While there are a range of reports that different foods and food groups can increase or decrease your risk of cancer, these associations are very difficult to scientifically verify.

27 Jan 2016

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology.

27 Jan 2016

AVAX announces results of Phase 1/2 OVAX study in patients with advanced ovarian cancer

AVAX Technologies, Inc., a pioneer in personalized cancer vaccines, today announced the results of its Phase 1/2 OVAX study in patients with platinum resistant relapsed Stage III or IV Ovarian Cancer.

26 Jan 2016

Palonosetron effective anti-emetic for paediatric chemotherapy patients

Palonosetron 20 μg/kg is noninferior to ondansetron for the control of chemotherapy-induced vomiting and nausea during the acute phase of the first treatment cycle in paediatric patients with cancer, research shows.

26 Jan 2016

Carbapenem-resistant Enterobacteriaceae: an interview with Dr. Michael Dudley

Enterobacteriaceae refer to the family of bacteria such as E. coli and Klebsiella that are bacterial pathogens most frequently associated with hospital-acquired infections

25 Jan 2016

Positive bosutinib response for elderly blast phase CML patient

A case study suggests that the third-generation tyrosine kinase inhibitor bosutinib may be considered as induction therapy for blast phase chronic myeloid leukaemia in older patients.

22 Jan 2016

Adjuvant Chemotherapy Colon Cancer Trials Should ‘Stratify By MSI, KRAS, BRAF’

A post hoc analysis of the PETACC-8 trial has revealed an interaction between microsatellite instability and BRAF and KRAS mutation status when determining the prognosis of patients with resected stage III colon adenocarcinoma.

22 Jan 2016

Researchers explore ways to use light to combat cancer

Immunotherapy is one of the hottest emerging areas of cancer research. After all, using the body's own cells to fight cancer can be more effective and less invasive than flooding the entire system with toxic chemicals.

22 Jan 2016

Colon cancer patients lacking CDX2 protein more likely to benefit from chemotherapy

Using a new computer science approach, researchers at University of California, San Diego School of Medicine, Columbia University and Stanford University discovered a distinctive molecular feature — a biomarker — that identified colon cancer patients who were most likely to remain disease-free up to five years after surgery.

22 Jan 2016

Simple blood test could predict relapse in AML patients

A simple blood test capable of detecting trace levels of leukaemia cells remaining after intensive chemotherapy has been developed by scientists at the National Institute for Health Research Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London.

22 Jan 2016

Immunotherapy could be the future of cancer treatments

For decades most cancers have been treated with the standard of care treatments which typically include surgery, radiation and/or chemotherapy. Now there is talk that immunotherapy represents "the future of cancer treatments."

21 Jan 2016

UM SOM study leads to FDA approval of Neulasta drug for treatment of radiation injury

As a result of research performed by scientists at the University of Maryland School of Medicine, the U.S. Food and Drug Administration has approved the use of a drug to treat the deleterious effects of radiation exposure following a nuclear incident. The drug, Neulasta, is one of a very small number that have been approved for the treatment of acute radiation injury.

21 Jan 2016

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

OncoGenex Pharmaceuticals, Inc. announced today that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit.

20 Jan 2016

Traditional acupuncture no better than fake acupuncture for treating menopause symptoms

A new study has revealed traditional Chinese acupuncture treatments are no better than fake acupuncture for treating menopause symptoms.

20 Jan 2016

NextSource Biotechnology announces FDA approval of Gleostine (lomustine) 5 mg capsules

NextSource Biotechnology, LLC announced today that Gleostine (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration and is now commercially available in the United States.

20 Jan 2016

New Penn study examines differences in costs of end-of-life care among developed countries

Despite widespread perception, the United States does not provide the worst end-of-life care in the world. In the first international comparison of end-of-life care practices, researchers from the Perelman School of Medicine at the University of Pennsylvania and colleagues from seven countries found that the United States actually has the lowest proportion of deaths in the hospital and the lowest number of days in the hospital in the last six months of life among the those countries, according to a new study published today in JAMA.

20 Jan 2016

Combining nanomedicine with two anticancer treatments could improve outcomes for pancreatic cancer patients

A nanoparticle drug-delivery system that combines two complementary types of anticancer treatment could improve outcomes for patients with pancreatic cancer and other highly treatment-resistant tumors while decreasing toxicity.

20 Jan 2016

Bevacizumab extends survival of pleural mesothelioma patients

Patients with unresectable, malignant pleural mesothelioma derive a significant survival benefit from the addition of bevacizumab to standard treatment according to phase III trial findings published in The Lancet.

19 Jan 2016

Chemotherapy News and Research

Latest Chemotherapy News and Research

Halaven (eribulin mesylate) approved for treatment of liposarcoma

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

Nutrition and breast cancer; starving triple negative breast cancer cells to death: an interview with Associate Professor Jeff Holst

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

AVAX announces results of Phase 1/2 OVAX study in patients with advanced ovarian cancer

Palonosetron effective anti-emetic for paediatric chemotherapy patients

Carbapenem-resistant Enterobacteriaceae: an interview with Dr. Michael Dudley

Positive bosutinib response for elderly blast phase CML patient

Adjuvant Chemotherapy Colon Cancer Trials Should ‘Stratify By MSI, KRAS, BRAF’

Researchers explore ways to use light to combat cancer

Colon cancer patients lacking CDX2 protein more likely to benefit from chemotherapy

Simple blood test could predict relapse in AML patients

Immunotherapy could be the future of cancer treatments

UM SOM study leads to FDA approval of Neulasta drug for treatment of radiation injury

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

Traditional acupuncture no better than fake acupuncture for treating menopause symptoms

NextSource Biotechnology announces FDA approval of Gleostine (lomustine) 5 mg capsules

New Penn study examines differences in costs of end-of-life care among developed countries

Combining nanomedicine with two anticancer treatments could improve outcomes for pancreatic cancer patients

Bevacizumab extends survival of pleural mesothelioma patients

Cancer Research - Second Edition eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in